Antonia Fettelschoss-Gabriel

Dr. Antonia Fettelschoss-Gabriel

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MKMagdalena Kistowska
Magdalena Kistowska
SGSamuel Gehrke
Samuel Gehrke
DJDragana Jankovic
Dragana Jankovic
KKKatrin Kerl
Katrin Kerl
AFAntonia Fettelschoss-Gabriel
Antonia Fettelschoss-Gabriel
LFLars E. French
Lars E. French

17 October 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AFAntonia Fettelschoss-Gabriel
Antonia Fettelschoss-Gabriel
MKMagdalena Kistowska
Magdalena Kistowska
Salomé Leibundgut-LandmannSalomé Leibundgut-Landmann
Salomé Leibundgut-Landmann
Hans-Dietmar BeerHans-Dietmar Beer
Hans-Dietmar Beer
Pål JohansenPål Johansen
Pål Johansen
TKThomas M. Kündig
Thomas M. Kündig
Interleukin-1α (IL-1α) and -β both bind to the same IL-1 receptor (IL-1R) and are potent proinflammatory cytokines. Production of proinflammatory (pro)–IL-1α and pro–IL-1β is induced by Toll-like receptor (TLR)-mediated NF-κB activation. Additional stimulus involving activation of the inflammasome and caspase-1 is required for proteolytic cleavage and secretion of mature IL-1β. The regulation of IL-1α maturation and secretion, however, remains elusive. IL-1α exists as a cell surface-associated form and as a mature secreted form. Here we show that both forms of IL-1α, the surface and secreted form, are differentially regulated. Surface IL-1α requires NF-κB activation only, whereas secretion of mature IL-1α requires additional activation of the inflammasome and caspase-1. Surprisingly, secretion of IL-1α also required the presence of IL-1β, as demonstrated in IL-1β–deficient mice. We further demonstrate that IL-1β directly binds IL-1α, thus identifying IL-1β as a shuttle for another proinflammatory cytokine. These results have direct impact on selective treatment modalities of inflammatory diseases.

1 February 2018 in Cell Reports
Verified
Journal Article
Open access
MSMarianne R. Spalinger
Marianne R. Spalinger
RMRoberto Manzini
Roberto Manzini
LHLarissa Hering
Larissa Hering
JRJulianne B. Riggs
Julianne B. Riggs
CGClaudia Gottier
Claudia Gottier
MSMichael Scharl
Michael Scharl
Variants in the gene locus encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) are associated with inflammatory disorders, including inflammatory bowel diseases, rheumatoid arthritis, and type 1 diabetes. The anti-inflammatory role of PTPN2 is highlighted by the fact that PTPN2-deficient mice die a few weeks after birth because of systemic inflammation and severe colitis. However, the tissues, cells, and molecular mechanisms that contribute to this phenotype remain unclear. Here, we demonstrate that myeloid cell-specific deletion of PTPN2 in mice (PTPN2-LysMCre) promotes intestinal inflammation but protects from colitis-associated tumor formation in an IL-1β-dependent manner. Elevated levels of mature IL-1β production in PTPN2-LysMCre mice are a consequence of increased inflammasome assembly due to elevated phosphorylation of the inflammasome adaptor molecule ASC. Thus, we have identified a dual role for myeloid PTPN2 in directly regulating inflammasome activation and IL-1β production to suppress pro-inflammatory responses during colitis but promote intestinal tumor development.

1 October 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
AFAntonia Fettelschoss-Gabriel
Antonia Fettelschoss-Gabriel
VFVictoria Fettelschoss
Victoria Fettelschoss
FTFranziska Thoms
Franziska Thoms
CGChristoph Giese
Christoph Giese
MDMichelle Daniel
Michelle Daniel
Martin BachmannMartin Bachmann
Martin Bachmann
Insect-bite hypersensitivity is the most common allergic dermatitis in horses. Excoriated skin lesions are typical symptoms of this seasonal and refractory chronic disease. On a cellular level, the skin lesions are characterized by massive eosinophil infiltration caused by an underlying allergic response. To target these cells and treat disease, we developed a therapeutic vaccine against equine IL-5 (eIL-5), the master regulator of eosinophils. The vaccine consisted of eIL-5 covalently linked to a virus-like particle derived from cucumber mosaic virus containing the tetanus toxoid universal T-cell epitope tt830-843 (CMVTT). Thirty-four Icelandic horses were recruited and immunized with 400 μg of eIL-5-CMVTT formulated in PBS without adjuvant (19 horses) or PBS alone (15 horses). The vaccine was well tolerated and did not reveal any safety concerns but was able to induce anti-eIL-5 autoantibody titers in 17 of 19 horses. This resulted in a statistically significant reduction in clinical lesion scores when compared with previous season levels, as well as levels in placebo-treated horses. Protection required a minimal threshold of anti-eIL-5 antibodies. Clinical improvement by disease scoring showed that 47% and 21% of vaccinated horses reached 50% and 75% improvement, respectively. In the placebo group no horse reached 75% improvement, and only 13% reached 50% improvement. Our therapeutic vaccine inducing autoantibodies against self IL-5 brings biologics to horses, is the first successful immunotherapeutic approach targeting a chronic disease in horses, and might facilitate development of a similar vaccine against IL-5 in human subjects.

1 July 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
FTFranziska Thoms
Franziska Thoms
GJGary T. Jennings
Gary T. Jennings
MMMelanie Maudrich
Melanie Maudrich
MVMonique Vogel
Monique Vogel
SHStefanie Haas
Stefanie Haas
Martin BachmannMartin Bachmann
Martin Bachmann
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms. We developed a new strategy to treat Fel d 1-induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1. A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843 (CuMVTT) was used to immunize cats. A first tolerability and immunogenicity study, including a boost injection, was conducted by using the Fel-CuMVTT vaccine alone or in combination with an adjuvant. The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti-Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed. Vaccination of cats with Fel-CuMVTT induces neutralizing antibodies and might result in reduced symptoms of allergic cat owners. Both human subjects and animals could profit from this treatment because allergic cat owners would reduce their risk of developing chronic diseases, such as asthma, and become more tolerant of their cats, which therefore could stay in the households and not need to be relinquished to animal shelters.

6 April 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
PDF file
Pål JohansenPål Johansen
Pål Johansen
AFAntonia Fettelschoss-Gabriel
Antonia Fettelschoss-Gabriel
BABeat Amstutz
Beat Amstutz
PSPetra Selchow
Petra Selchow
YWYing Waeckerle-Men
Ying Waeckerle-Men
PSPeter Sander
Peter Sander
Pathogenic mycobacteria escape host innate immune responses by blocking phagosome-lysosome fusion. Avoiding lysosomal delivery may also be involved in the capacity of mycobacteria to evade major histocompatibility complex (MHC) class I- or II-dependent T-cell responses. In this study, we used a genetic mutant ofMycobacterium bovisBCG that is unable to escape lysosomal transfer and show that presentation of mycobacterial antigens is affected by the site of intracellular residence. Compared to infection with wild-type BCG, infection of murine bone marrow-derived dendritic cells with a mycobacterial mutant deficient in zinc metalloprotease 1 (Zmp1) resulted in increased presentation of MHC class II-restricted antigens, as assessed by activation of mycobacterial Ag85A-specific T-cell hybridomas. Thezmp1deletion mutant was more immunogenicin vivo, as measured by delayed-type hypersensitivity (DTH), antigen-specific lymphocyte proliferation, and the frequency of antigen-specific gamma interferon (IFN-γ)-producing lymphocytes of both CD4 and CD8 subsets. In conclusion, our results suggest that phagosome maturation and lysosomal delivery of BCG facilitate mycobacterial antigen presentation and enhance immunogenicity.